Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Pfizer to Acquire Ferrosan’s Consumer Healthcare Business

By Pharmaceutical Processing | February 7, 2011

Pfizer Inc. today announced that it has entered into a
definitive agreement to purchase Ferrosan’s consumer healthcare business, which
includes dietary supplements and lifestyle products, from Altor 2003 Fund GP
Limited.

Based in Copenhagen,
Ferrosan is an innovative and long-established consumer healthcare company in
the Nordic region with a portfolio of leading brands. Since 1920, Ferrosan has
grown to serve a broader market including Russia,
the Ukraine, Poland, Turkey
and many countries throughout Central and Eastern Europe.

“Ferrosan is an excellent strategic fit that strengthens our
presence in dietary supplements with a new set of compelling brands and product
pipeline,” said Paul Sturman, president, Pfizer Consumer Healthcare. “The
transaction will mark an important step towards expanding Ferrosan’s brands
through Pfizer’s global footprint. As an immediate result of this acquisition,
we will gain greater distribution and scale for Pfizer’s well-known brands such
as Centrum® and Caltrate® in Ferrosan’s regions.”

Ferrosan’s portfolio of products include Multi-tabs®, a
popular multivitamin brand, Bifiform®, a leading probiotic, Fri Flyt/Active
Omega, an Omega 3 product, and IMEDEEN® premium oral skincare brands. These Ferrosan
brands are among the top-selling products in their respective categories.

Ola Erici, President of Ferrosan, said, “We are very pleased
that Ferrosan’s innovative portfolio of leading brands will be joining Pfizer.
We expect that, as part of the Pfizer portfolio, our products will build on
their industry-leading positions and become available in more countries around
the world. And, at the same time, Pfizer will be able to leverage its footprint
in key Ferrosan markets with new Pfizer products.”

The transaction, which is subject to customary closing
conditions, including regulatory approval in certain jurisdictions, is expected
to close during the second quarter 2011. Financial terms were not disclosed.

Pfizer’s financial advisors were Barclays Capital and
Guggenheim Securities, LLC. Skadden, Arps, Slate, Meagher & Flom LLP acted
as U.S.
counsel for Pfizer with Gorrissen Federspiel advising Pfizer on Danish law.

 

Related Articles Read More >

A Zipline fixed-wing drone in the air drops a package
Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Image of MedTrace Pharma's P3 automated delivery system for 15-O water in action
MedTrace Pharma moves forward on 15 O-water imaging tech
coronavirus COVID-19 Pfizer
NIH starts evaluating second COVID-19 booster shots in adults

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards